Hyman B. Muss, MD, UNC Lineberger Comprehensive Cancer Center, UNC School of Medicine, discusses adjuvant therapy for elderly patients with HER2-positive or triple negative breast cancer (TNBC).
Hyman B. Muss, MD, UNC Lineberger Comprehensive Cancer Center, UNC School of Medicine, discusses adjuvant therapy for elderly patients with HER2-positive or triple negative breast cancer (TNBC).
Breast Cancer Leans into the Decade of Antibody-Drug Conjugates, Experts Discuss
September 25th 2020In season 1, episode 3 of Targeted Talks, the importance of precision medicine in breast cancer, and how that vitally differs in community oncology compared with academic settings, is the topic of discussion.
Listen
Comparing Elacestrant Vs Fulvestrant for ESR1-Mutated Breast Cancer
May 10th 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Claudine Isaacs, MD, discussed with participants what they see as the role of elacestrant for patients with ER+, HER2-negative breast cancer. This is the second of 2 articles based on this event.
Read More
2 Clarke Drive
Cranbury, NJ 08512